Track 6: Translational Sciences and Precision Medicine
Preclinical and early-phase clinical research provides initial dosing and safety data for new drugs. This track focuses on the latest strategies used in early-stage compound selection, updates on safety considerations for both drugs and biologics, how PK/PD affects dosing strategies, and methods to improve data quality and integrity for proper downstream decision-making.
DIA recommends this track and associated sessions to professionals involved in pharmacology and toxicology, nonclinical safety testing, clinical research, clinical operations, safety and pharmacovigilance, project management, patient centricity, and statistics; formulation science, pharmacokinetics/pharmacodynamics, epidemiology, toxicology, and regulatory affairs.
Included Topic Areas
View Included Priority Topic Areas
Personalized medicine, clinical trial data disclosure, collaborations, bioethics, compliance, stem cells, regenerative therapies, cell and gene therapies, gene editing, organoids/micro-physiological systems, ICH (S), study endpoints, integration of the ‘patient’s voice’ early in preclinical development to define/refine the patient population and clinical endpoints, preclinical studies, and challenges in rare and common diseases. Topics related to bioethical issues are also welcome and may be considered for a special track in the meeting.
- Innovations in Early Development of Vaccines: Translation from Pre-Clinical to Clinical
- Diversity, Equity, and Inclusion in Early Drug Development
- What’s New in Gene Therapy
- What’s New in Gene Editing
- Innovative New Models and Methods for Medical Product Development
- Early Development Decisions and Mitigating Challenges in Rare Disease Drug Development
- Precision Medicines in Early-Phase Clinical Development
- The Microbiome Factor in Drug Discovery and Development
Sessions in Translational Sciences and Precision Medicine
View Included Priority Topic Areas